Christopher P. Stewart - Feb 15, 2023 Form 4 Insider Report for Bionano Genomics, Inc. (BNGO)

Role: Chief Financial Officer
Signature: /s/ R. Erik Holmlin, Attorney-in-Fact
Stock symbol: BNGO
Transactions as of: Feb 15, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/17/2023, 06:20 PM
Previous filing: May 16, 2022
Next filing: May 16, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BNGO	Common Stock	Award	$0	+105K	+83.09%	$0.00	231K	Feb 15, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BNGO	Stock Option (Right to Buy)	Award	$0	+490K		$0.00	490K	Feb 15, 2023	Common Stock	490K	$1.63	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan.
F2	Includes 2,285 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 10, 2022 and 2,509 shares acquired under the ESPP on December 10, 2022.
F3	The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2023 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.